Few diseases have wreaked as much havoc as malaria. In 2019, there were an estimated 229 million malaria cases. More than 400,000 people worldwide die from the mosquito-borne disease every year. Roughly two-thirds of those deaths are kids aged 5 or younger.
But now help is on the way. Last week, the World Health Organization (WHO) recommended widespread use of a malaria vaccine in children. WHO Director-General Tedros Adhanom Ghebreyesus called this recommendation "a historic moment." Ghebreyesus said, "The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control."
Potentially tens of thousands of children, primarily in Africa, should benefit from this malaria vaccine. And there are also two vaccine stocks that are poised to win as well -- GlaxoSmithKline (NYSE: GSK) and Agenus (NASDAQ: AGEN) .
For further details see:
2 Stocks Set to Win From the Historic Malaria Vaccine Approval